Autoaggressive, myelin-reactive T cells are involved in multiple sclerosis and its prototype experimental autoimmune encephalomyelitis (EAE) in mice. A peripheral negative feedback mechanism involving regulatory CD4+ and CD8+T cells (Treg) operates to suppress disease-mediating T cell responses. We have recently characterized a novel population of Qa-1a-restricted, TCR-peptide-reactive CD8αα+TCRαβ+ Treg that induce apoptotic depletion of the encephalitogenic Vβ8.2 cells in vivo and provide protection from EAE. Here we have used mice deficient in perforin, Fas/FasL and IFN-γ molecules to investigate their role in Tregmediated regulation of EAE. Data show that Fas/FasL interactions are not involved, but regulation mediated by Treg is dependent on the presence of IFN-γ and the perforin pathway. These data provide a molecular mechanism of Treg-mediated killing of the pathogenic T cells and have important implications in the design of immune interventions for demyelinating disease.
Introduction
Experimental autoimmune encephalomyelitis (EAE) in rodents is a prototype for multiple sclerosis (MS) in humans; both are autoimmune diseases resulting from aggressive immune responses that destroy the myelin sheath surrounding axonal processes within the central nervous system. T cells have been demonstrated to be mediators of EAE (Steinman, 1996; Martin, 2008) , and are detected in the inflammatory infiltrate lesions in the brain and spinal cord of MS patients (Traugott et al., 1983; Hauser et al., 1986) . On the one hand, functional cytotoxic CD8+ T cells reactive to MBP have been shown to induce EAE (Steinman, 1996; Martin, 2008; Huseby et al., 2001) , on the other, CD8+ T cells with regulatory functions can suppress EAE disease processes (Jiang et al., 2001; Hu et al., 2004; Tang et al., 2006 Tang et al., , 2007 Smith and Kumar, 2008) . The Fas/FasL pathway has been implicated in both the regulation of disease (Sabelko-Downes et al., 1999) and pathogenesis associated with CD8+ T cells during EAE (Sabelko et al., 1997; Sabelko-Downes et al., 2000; Waldner et al., 1997) . Thus, dual roles for both CD8+ T cells and Fas/FasL pathway in EAE have been reported.
The role of regulatory T cells is one of the most promising areas of autoimmune disease research and has become an important new target for therapeutic intervention. Both regulatory CD4+ and CD8+ T cells have been shown to be protective against MS and EAE (Tang et al., 2006, 2007; Kumar and Sercarz, 1993; Zhang et al., 1993; Viglietta et al., 2004; Reddy et al., 2005) . In the EAE model we have delineated a negative feedback regulatory pathway that involves CD4+ and CD8αα+TCRαβ+ Treg operating in unison to down-regulate the disease-mediating Vβ8.2 CD4+ T cell population (Tang et al., 2006 (Tang et al., , 2007 Smith and Kumar, 2008; Kumar and Sercarz, 1993; Madakamutil et al., 2003) .
EAE is characterized by inflammation and demyelination of the central nervous system (CNS), and is mediated by dysregulated myelin-reactive T cells that can be induced in a variety of mouse strains by active immunization with specific myelin antigens or passive transfer of activated myelin-reactive T cells. In the H-2 u mice EAE is mediated by a population of predominantly TCRVβ8.2+ CD4+ T cells recognizing an immunodominant determinant from the N-terminal of myelin basic protein (MBP) (Acha-Orbea et al., 1988; Urban et al., 1988; Kumar et al., 1989) . In H-2 u mice EAE is generally monophasic, and most animals recover spontaneously. These mice are then resistant to re-induction of disease. Previous studies have shown that CD8+ T cells perform an essential role in protecting H-2 u mice from re-induction of disease (Sun et al., 1988; Jiang et al., 1992; Koh et al., 1992) . Here we have examined the mechanism of recovery from MBPAc1-9-induced EAE and how it is facilitated by the coordinated action of regulatory CD4+ and CD8αα+TCRαβ+ Treg cells that target the disease-mediating Vβ8.2+ T cells (Smith and Kumar, 2008; Kumar and Sercarz, 1993; Madakamutil et al., 2003) . Regulatory CD4+ cells predominantly express the Vβ14 TCR and recognize a framework 3 region determinant (B5 peptide, aa 76-101) from the Vβ8.2 chain.
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